Gyre Therapeutics (GYRE) Gross Margin (2020 - 2026)
Gyre Therapeutics (GYRE) reported Gross Margin of 37.23% for Q1 2026, down 5872.0% year-over-year from 0.64% in Q1 2025, and up 156.96% quarter-over-quarter from 65.36% in Q4 2025.
Gyre Therapeutics (GYRE) Gross Margin (2020 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 7 years of Gross Margin data on file, last reported at 37.23% in Q1 2026.
- Gross Margin for Q1 2026 came in at 37.23%, down 5872.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 33.0% (down 6322.0% YoY), and the FY2025 annual result was 44.09%, down 5223.0% from the prior year.
- Gross Margin improved to 37.23% in Q1 2026 per GYRE's latest filing, from 65.36% in the prior quarter.
- Over five years, Gross Margin peaked at 96.95% in Q2 2024 and troughed at 65.36% in Q4 2025.
- A 5-year average of 71.59% and a median of 95.7% in 2025 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2025: Gross Margin jumped 9599 bps in 2023, then sank 16114 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 47.35% in 2022, then jumped by 101 bps to 95.4% in 2023, then gained by 0 bps to 95.78% in 2024, then plunged by 168 bps to 65.36% in 2025, then jumped by 157 bps to 37.23% in 2026.
- Business Quant data shows GYRE's Gross Margin at 37.23% in Q1 2026, 65.36% in Q4 2025, and 94.67% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 37.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.23% |
| Dec 31, 2025 | -65.36% |
| Sep 30, 2025 | 94.67% |
| Jun 30, 2025 | 95.70% |
| Mar 31, 2025 | 95.95% |
| Dec 31, 2024 | 95.78% |
| Sep 30, 2024 | 96.24% |
| Jun 30, 2024 | 96.95% |
| Mar 31, 2024 | 96.40% |
| Dec 31, 2023 | 95.40% |
| Sep 30, 2023 | 96.30% |
| Jun 30, 2023 | 96.33% |
| Mar 31, 2023 | 95.49% |
| Dec 31, 2022 | 47.35% |
| Mar 31, 2022 | -0.50% |
| Dec 31, 2021 | -0.57% |
| Sep 30, 2021 | -0.35% |
| Jun 30, 2021 | -0.62% |
| Mar 31, 2021 | -0.89% |
| Dec 31, 2020 | -45.69% |